JPRN-C000000457已完成2 期
A prospective non-randomised phase II study to assess the safety and efficacy of melphalan combined with fludarabine as a reduced conditioning regimen for unrelated bone marrow transplantation for hematological malignancies (C-SHOT 0505) - A phase II study of melphalan combined with fludarabine for UBMT (C-SHOT 0505)
agoya Blood and Marrow Transplantation Group0 个研究点目标入组 54 人开始时间: 2006年7月31日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16years-old 至 55years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Positive for HIV antibody and/or HBs antigen and/or HCV antibody, (2)Graft manipulation such as T-cell depletion, (3)history of administration of anti-neoplastic agent within 4 weeks before transplantation (4)30% or more tumor cells of total nucleated cell count in bone marrow specimen before 28 days of registration (5)Pregnant or during breast feeding, (6)Uncontrolled another neoplastic disease, (7)Uncontrolled active psychiatric disease,(8)Uncontrolled active infection, (9)central nervous system involvement of tumor cells (10)Allergic history to drugs used in the present conditioning regimen or GVHD prophylaxis regimen, (11) Available of a suitable related donor, (12)Patients suggested as ineligible by their attending physician
研究者
相似试验
已完成
2 期
A prospective non-randomized phase II study to assess the efficacy of unrelated cord blood transplantation for adult unfavorable hematological malignancies (C-SHOT 0601)Patients with acute myeloid leukemia/acute lymphocytic leukemia/myelodysplastic syndrome/chronic myelomonocytic leukemia categorized as high risk groupJPRN-UMIN000000600agoya Blood and Marrow Transplantation Group60
尚未招募
2 期
Study to evaluate the response to treatment with the medication pasireotide LAR and the expression of the substances AIP and miR-34a in patients with acromegalyE22.0AcromegalyRBR-29grfmFaculdade de Medicina - Universidade Federal do Rio de Janeiro (UFRJ)
进行中（未招募）
不适用
A randomized trial to identify markers for personalized treatment in patients treated with bevacizumab and paclitaxel for advanced breast cancerAdvanced breast cancerEUCTR2012-003743-30-SEKarolinska University Hospital
进行中（未招募）
不适用
A prospective randomized phase II study evaluating the monitoring of imatinib mesylate (Gliveec®) plasmatic through level in patients newly diagnosed with chronic phase chronic myelogenous leukaemia (CP-CML). - OPTIM IMATINIBChronic Phase Chronic myelogenous leukemia (CP CML)EUCTR2010-019568-35-FRCH VERSAILLES
进行中（未招募）
1 期
A study to assess the schemas of retreatment with Lutathera® in patients with new progression of intestinal well-differentiated neuroendocrine tumor.EUCTR2021-001306-30-FRInstitut Régional du Cancer de Montpellier146